Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1995 May;115(1):3–10. doi: 10.1111/j.1476-5381.1995.tb16311.x

Discrimination by benextramine between the NPY-Y1 receptor subtypes present in rabbit isolated vas deferens and saphenous vein.

S Palea 1, M Corsi 1, J M Rimland 1, D G Trist 1
PMCID: PMC1908753  PMID: 7647980

Abstract

1. In order to characterize the neuropeptide Y (NPY) Y1 receptors known to be present in rabbit isolated vas deferens and saphenous vein, the pharmacological activity of the selective NPY Y1 receptor agonists, [Leu31,Pro34] NPY and various other peptide agonists, together with the putative NPY antagonist, benextramine, were compared in the two tissues. 2. In rabbit isolated saphenous vein, cumulative dose-response curves to various NPY agonists were obtained. All the peptides tested caused contractions which developed quite slowly. The rank order of potency obtained was: PYY > NPY > [Leu31,Pro34] NPY = NPY2-36 > hPP >> NPY13-36 = NPY18-36. Incubation with benextramine (BXT) at 100 microM for 30 min irreversibly abolished the contractile response to [Leu31,Pro34] NPY but was ineffective against NPY18-36-induced contractions. 3. Cumulative dose-response curves to [Leu31,Pro34] NPY were performed in the same preparation before and after incubation with 100 microM BXT for 20 min in order to inactivate NPY Y1 receptors. The pKA (-logKA) estimation for [Leu31,Pro34] NPY was 7.60 +/- 0.30 using the operational model and 7.20 +/- 0.33 using the null method; the difference between the two methods was not statistically significant (P = 0.36). 4. Prostatic segments of rabbit vas deferens were electrically stimulated with single pulses. Immediately after stabilization of the contractile response, a cumulative dose-response curve to various NPY agonists was obtained in each tissue.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
3

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Balasubramaniam A., Sheriff S., Rigel D. F., Fischer J. E. Characterization of neuropeptide Y binding sites in rat cardiac ventricular membranes. Peptides. 1990 May-Jun;11(3):545–550. doi: 10.1016/0196-9781(90)90057-c. [DOI] [PubMed] [Google Scholar]
  2. Black J. W., Leff P., Shankley N. P., Wood J. An operational model of pharmacological agonism: the effect of E/[A] curve shape on agonist dissociation constant estimation. Br J Pharmacol. 1985 Feb;84(2):561–571. doi: 10.1111/j.1476-5381.1985.tb12941.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cadieux A., Pheng L. H., St-Pierre S., Fournier A., Benchekroun M. T. The rabbit saphenous vein: a tissue preparation specifically enriched in NPY-Y1 receptor subtype. Regul Pept. 1993 Jul 23;46(3):557–564. doi: 10.1016/0167-0115(93)90257-9. [DOI] [PubMed] [Google Scholar]
  4. Doods H. N., Krause J. Different neuropeptide Y receptor subtypes in rat and rabbit vas deferens. Eur J Pharmacol. 1991 Oct 29;204(1):101–103. doi: 10.1016/0014-2999(91)90841-d. [DOI] [PubMed] [Google Scholar]
  5. Doughty M. B., Li K., Hu L., Chu S. S., Tessel R. Benextramine-neuropeptide Y (NPY) binding site interactions: characterization of 3H-NPY binding site heterogeneity in rat brain. Neuropeptides. 1992 Nov;23(3):169–180. doi: 10.1016/0143-4179(92)90119-h. [DOI] [PubMed] [Google Scholar]
  6. Ekblad E., Edvinsson L., Wahlestedt C., Uddman R., Håkanson R., Sundler F. Neuropeptide Y co-exists and co-operates with noradrenaline in perivascular nerve fibers. Regul Pept. 1984 Apr;8(3):225–235. doi: 10.1016/0167-0115(84)90064-8. [DOI] [PubMed] [Google Scholar]
  7. Foucart S., Bleakman D., Bindokas V. P., Miller R. J. Neuropeptide Y and pancreatic polypeptide reduce calcium currents in acutely dissociated neurons from adult rat superior cervical ganglia. J Pharmacol Exp Ther. 1993 May;265(2):903–909. [PubMed] [Google Scholar]
  8. Fuhlendorff J., Gether U., Aakerlund L., Langeland-Johansen N., Thøgersen H., Melberg S. G., Olsen U. B., Thastrup O., Schwartz T. W. [Leu31, Pro34]neuropeptide Y: a specific Y1 receptor agonist. Proc Natl Acad Sci U S A. 1990 Jan;87(1):182–186. doi: 10.1073/pnas.87.1.182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Grundemar L., Håkanson R. Multiple neuropeptide Y receptors are involved in cardiovascular regulation. Peripheral and central mechanisms. Gen Pharmacol. 1993 Jul;24(4):785–796. doi: 10.1016/0306-3623(93)90151-m. [DOI] [PubMed] [Google Scholar]
  10. Grundemar L., Jonas S. E., Mörner N., Högestätt E. D., Wahlestedt C., Håkanson R. Characterization of vascular neuropeptide Y receptors. Br J Pharmacol. 1992 Jan;105(1):45–50. doi: 10.1111/j.1476-5381.1992.tb14208.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Grundemar L., Wahlestedt C., Reis D. J. Long-lasting inhibition of the cardiovascular responses to glutamate and the baroreceptor reflex elicited by neuropeptide Y injected into the nucleus tractus solitarius of the rat. Neurosci Lett. 1991 Jan 14;122(1):135–139. doi: 10.1016/0304-3940(91)90211-b. [DOI] [PubMed] [Google Scholar]
  12. Grundemar L., Wahlestedt C., Reis D. J. Neuropeptide Y acts at an atypical receptor to evoke cardiovascular depression and to inhibit glutamate responsiveness in the brainstem. J Pharmacol Exp Ther. 1991 Aug;258(2):633–638. [PubMed] [Google Scholar]
  13. Illes P., Nörenberg W. Neuronal ATP receptors and their mechanism of action. Trends Pharmacol Sci. 1993 Feb;14(2):50–54. doi: 10.1016/0165-6147(93)90030-n. [DOI] [PubMed] [Google Scholar]
  14. Jørgensen J. C., Fuhlendorff J., Schwartz T. W. Structure-function studies on neuropeptide Y and pancreatic polypeptide--evidence for two PP-fold receptors in vas deferens. Eur J Pharmacol. 1990 Sep 4;186(1):105–114. doi: 10.1016/0014-2999(90)94065-6. [DOI] [PubMed] [Google Scholar]
  15. Li W., MacDonald R. G., Hexum T. D. Benextramine irreversibly inhibits [125I]neuropeptide Y affinity labeling of the Y2 binding protein in bovine hippocampus. Eur J Pharmacol. 1991 May 25;207(1):89–91. doi: 10.1016/s0922-4106(05)80042-2. [DOI] [PubMed] [Google Scholar]
  16. McAuley M. A., Westfall T. C. Possible location and function of neuropeptide Y receptor subtypes in the rat mesenteric arterial bed. J Pharmacol Exp Ther. 1992 Jun;261(3):863–868. [PubMed] [Google Scholar]
  17. McKinney M., Stenstrom S., Richelson E. Muscarinic responses and binding in a murine neuroblastoma clone (N1E-115). Selective loss with subculturing of the low-affinity agonist site mediating cyclic GMP formation. Mol Pharmacol. 1984 Sep;26(2):156–163. [PubMed] [Google Scholar]
  18. Michel M. C., Gaida W., Beck-Sickinger A. G., Wieland H. A., Doods H., Dürr H., Jung G., Schnorrenberg G. Further characterization of neuropeptide Y receptor subtypes using centrally truncated analogs of neuropeptide Y: evidence for subtype-differentiating effects on affinity and intrinsic efficacy. Mol Pharmacol. 1992 Oct;42(4):642–648. [PubMed] [Google Scholar]
  19. Plotek Y., Atlas D. Characterization of benextramine as an irreversible alpha-adrenergic blocker and as a blocker of potassium-activated calcium channels. Eur J Biochem. 1983 Jul 1;133(3):539–544. doi: 10.1111/j.1432-1033.1983.tb07497.x. [DOI] [PubMed] [Google Scholar]
  20. Rioux F., Bachelard H., Martel J. C., St-Pierre S. The vasoconstrictor effect of neuropeptide Y and related peptides in the guinea pig isolated heart. Peptides. 1986 Jan-Feb;7(1):27–31. doi: 10.1016/0196-9781(86)90056-2. [DOI] [PubMed] [Google Scholar]
  21. Schwartz T. W., Fuhlendorff J., Kjems L. L., Kristensen M. S., Vervelde M., O'Hare M., Krstenansky J. L., Bjørnholm B. Signal epitopes in the three-dimensional structure of neuropeptide Y. Interaction with Y1, Y2, and pancreatic polypeptide receptors. Ann N Y Acad Sci. 1990;611:35–47. doi: 10.1111/j.1749-6632.1990.tb48920.x. [DOI] [PubMed] [Google Scholar]
  22. Schwartz T. W., Sheikh S. P., O'Hare M. M. Receptors on phaeochromocytoma cells for two members of the PP-fold family--NPY and PP. FEBS Lett. 1987 Dec 10;225(1-2):209–214. doi: 10.1016/0014-5793(87)81159-6. [DOI] [PubMed] [Google Scholar]
  23. Stjärne L., Lundberg J. M., Astrand P. Neuropeptide Y--a cotransmitter with noradrenaline and adenosine 5'-triphosphate in the sympathetic nerves of the mouse vas deferens? A biochemical, physiological and electropharmacological study. Neuroscience. 1986 May;18(1):151–166. doi: 10.1016/0306-4522(86)90184-3. [DOI] [PubMed] [Google Scholar]
  24. Tessel R. E., Miller D. W., Misse G. A., Dong X., Doughty M. B. Characterization of vascular postsynaptic neuropeptide Y receptor function and regulation. 1. NPY-induced constriction in isolated rat femoral artery rings is mediated by both Y1 and Y2 receptors: evidence from benextramine protection studies. J Pharmacol Exp Ther. 1993 Apr;265(1):172–177. [PubMed] [Google Scholar]
  25. Wahlestedt C., Reis D. J. Neuropeptide Y-related peptides and their receptors--are the receptors potential therapeutic drug targets? Annu Rev Pharmacol Toxicol. 1993;33:309–352. doi: 10.1146/annurev.pa.33.040193.001521. [DOI] [PubMed] [Google Scholar]
  26. Wahlestedt C., Yanaihara N., Håkanson R. Evidence for different pre-and post-junctional receptors for neuropeptide Y and related peptides. Regul Pept. 1986 Feb;13(3-4):307–318. doi: 10.1016/0167-0115(86)90048-0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES